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Abstract X-linked Alport syndrome (XLAS) is caused by
mutations in type IV collagen causing sensorineural hearing
loss, eye abnormalities, and progressive kidney dysfunction
that results in near universal end-stage renal disease (ESRD)
and the need for kidney transplantation in affected males.
Until recent decades, the disease burden in heterozygous
“carrier” females was largely minimized or ignored. Hetero-
zygous females have widely variable disease outcomes, with
some affected females exhibiting normal urinalysis and
kidney function, while others develop ESRD and deafness.
While the determinants of disease severity in females with
XLAS are uncertain, skewing of X-chromosome inactivation
has recently been found to play a role. This review will
explore the natural history of heterozygous XLAS females,
the determinants of disease severity, and the utility of using
XLAS females as kidney donors.
Keywords X-chromosome inactivation.Glomerular
basement membrane.Kidney transplantation.Type IV
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Introduction
Alport syndrome (AS) is a progressive, inherited disorder
of basement membranes that classically presents with
microscopic hematuria. Other characteristic features include
sensorineural deafness, anterior lenticonus, and progressive
kidney dysfunction leading to end-stage renal disease
(ESRD) [1]. AS is a relatively common genetic cause of
ESRD in the pediatric population, with familial nephritis
accounting for 2.3% of pediatric kidney transplants and
1.9% of the pediatric dialysis population according to the
2008 report of the North American Pediatric Renal Trials
and Collaborative Studies (NAPRTCS) [2].
AS is caused by mutations in type IV collagen, a major
constituent of basement membranes [3]. Six isoforms of
type IV collagen, α1(IV)–α6(IV), encoded by six genes,
COL4A1–COL4A6, are variably expressed in basement
membranes. These type IV collagen chains self assemble
to form specific triple helixes that then form a tertiary
network together with laminin, entactin/nidogen, and
proteoglycans to ultimately form the basement membranes.
The α3-α4-α5(IV) network is the predominant type IV
collagen network in the mature glomerular basement
membrane (GBM) and certain basement membranes of the
cochlea and eye [3]. Mutations in the α3, α4, or α5 chain
of type IV collagen lead to the loss or disruption of the α3-
α4-α5(IV) network, dysfunction of the affected basement
membranes, and the clinical manifestations of AS [1].
There are three common patterns of inheritance in Alport
families. About 80% of AS is inherited in an X-linked
manner (XLAS) and caused by mutations in COL4A5 on
the X chromosome. Nearly all affected males will develop
ESRD, while heterozygous females exhibit a wide variabil-
ity in disease severity [4, 5]. Nearly 90% of males with
XLAS reach ESRD by age 40 years, while only 12% of
heterozygous females do the same [4]. About 15% of AS is
inherited in an autosomal recessive manner (ARAS) due to
mutations in both alleles of either COL4A3 or COL4A4.
Autosomal dominant AS is quite rare (about 5% of families)
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or COL4A4 [6]. For the remainder of this review, I will focus
on heterozygous females with COL4A5 mutations. I will
specifically avoid the term “carrier” as this implies a benign
or silent phenotype.
Kidney biopsies from heterozygous AS females have a
widely variable appearance, with nonspecific findings
detected by light microscopy, ranging from a normal
appearance to mesangial proliferation to interstitial fibrosis.
Electron microscopy may reveal thinning of the GBM early
in the disease course; however, the GBM may also have a
normal appearance. Later in the disease course, classic
thickening and lamellation of the GBM with overlying
focal or diffuse podocyte foot process effacement may be
evident in severely affected females [1]. Immunostaining
for α3(IV), α4(IV), and α5(IV) in affected males demon-
strates the absence of these collagen chains in the GBM in
approximately 80% of patients. In heterozygous females, a
mosaic GBM staining pattern is evident in 60–70% of
females due to X-chromosome inactivation (Fig. 1). Skin
biopsies have become an accepted method for diagnosing
XLAS in order to avoid a more invasive renal biopsy. α5
(IV) along with α6(IV) are normally present in the
epidermal basement membrane (EBM) in the form of α5-
α5-α6(IV) networks. Immunostaining for α5(IV) demon-
strates its absence from the EBM in most affected males,
while a discontinuous staining pattern is apparent in
60–70% of heterozygous females [1]. One group reported
a heterozygous female with normal α5(IV) immunostaining
in the GBM and a discontinuous staining pattern in the
EBM [7]. The reason for this discrepancy is unclear but
may reflect different X inactivation patterns in different
tissues [8].
Natural history of heterozygous females
For much of the 20th century, affected females in families
with AS were assumed to follow a benign course. Alport
himself wrote in 1927 that “the females have deafness and
hematuria and live to old age” [9]. Interestingly, the family
first reported by Alport included a female with hematuria
and deafness who died at 24 years of age. Even in the
1960s investigators believed that “females usually remain
well throughout life…and only rarely have women died of
the disease” [10]. However, in the 1960s and 1970’s case
reports about severely affected females started to appear in
the literature [11]. In 1985, a report from Hôpital Necker in
Paris described the natural history of 36 women from 24
families with hereditary nephritis [12]. One quarter of
heterozygous females progressed to ESRD prior to age 35
years, while another 14% reached end stage after age 45
years. Predictors of progressive kidney disease in this
cohort included gross hematuria in childhood, nephrotic
syndrome, and diffuse GBM thickening as evidenced by
electron microscopy. This was one of the first indications to
the renal community that heterozygous females with AS
were at significant risk for progression to ESRD.
The most extensive natural history study of heterozygous
females was performed by the European Community Alport
Syndrome Concerted Action Study and published in 2003
[4]. The investigators characterized 349 heterozygous
females from 195 families with proven COL4A5 mutations
and compared them to affected hemizygous males within
the same families. Microscopic hematuria was found in
95.5% of XLAS heterozygotes. Thus, although nearly
universal in heterozygotes, the absence of microscopic
hematuria can not exclude XLAS carrier status. Surprising-
ly, 75% of XLAS heterozygotes developed proteinuria. As
with other renal diseases, the presence of proteinuria was a
significant risk factor for progression to ESRD (p<0.001).
While nearly 90% of affected males developed ESRD by
age 40 years, only 12% of heterozygous females in this
study did the same (Fig. 2). After age 60 years, between
30–40% of heterozygotes developed ESRD. These data
confirmed a substantial burden of kidney disease in this all-
female population, in stark contrast to the previously
accepted “benign carrier” designation.
Fig. 1 Glomeruli from a single heterozygous X-linked Alport
syndrome (XLAS) mouse demonstrate a wide variability in α5(IV)
expression due to X-inactivation, ranging from nearly absent (left panel)
to nearly normal (right panel). Immunohistochemistry was performed as
previously published [23]u s i n gr a ta n t i - α5(IV) antibodies (courtesy of
Y. Sado). Images courtesy of Y. Segal
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heterozygous females, with the risk increasing with age [4].
By age 40 years, approximately 90% of affected males had
hearing loss versus 10% in heterozygous females. The
presence of hearing loss in heterozygous females was also a
risk factor for progression to ESRD (p=0.02).
Determinants of disease severity in heterozygous
females
The explanation for the wide variability in outcomes for
heterozygous females is uncertain, but likely multifactorial.
In affected males there is a significant genotype–phenotype
correlation in that nonsense mutations and large deletions
are more likely to lead to early ESRD than missense or
splice site mutations [5]. In females, these genotype–
phenotype correlations are not observed [4]. There is also
inconsistency in phenotype between females within the
same family. Thus, genotype does not seem to be a major
determinant of phenotypic heterogeneity in XLAS females.
Over the years, several investigators have suggested that
differences in X chromosome inactivation may influence
disease severity in heterozygous females [13, 14]. X
chromosome inactivation is used by mammalian cells to
equalize gene dosage between the XX female and the XY
male [15]. Very early in development, either the maternal or
paternal X chromosome is randomly silenced through a
complex cellular machinery [16]. This inactivation choice is
passed on to all progeny cells, resulting in a female being a
mosaic of cells with either the maternal or paternal X
chromosome active [15]. In a typical female, 50% of the
active X-chromosomes would be of maternal origin while
the remaining 50% would be of paternal origin. However,
X-inactivation ratios can be skewed due to chance, X
chromosome anomalies, X-inactivation modifier genes,
such as Xce in the mouse, or mutation selection advantage.
X-inactivation has long been thought to be a stable,
irreversible phenomenon; however, recent data indicate that
some genes can “escape” from X- inactivation [17]. In
addition, cells with rapid turnover, such as peripheral blood
cells, can demonstrate increased skewing of X-inactivation
with age, thought to be due to selection pressure [18].
X-inactivation and Alport females
Severe skewing of X-inactivation in favor of expression of
the mutant COL4A5 has been reported to be responsible for
a severe Alport phenotype in two heterozygous females
[19, 20]. The first report was of a woman who reached
ESRD by age 30 years and was found to have two separate
COL4A5 mutations on the same chromosome [19]. In white
blood cells and kidney biopsy tissue, >90% of the mRNA
messages contained the COL4A5 mutations, suggesting that
the mutant X chromosome was being preferentially
expressed. The cause for the severe skewing was not
determined, although Turner syndrome (XO) was excluded.
In the second report, a heterozygous female with early
sensorineural hearing loss and kidney disease was found to
have a balanced translocation t(X;1)(q22.3;p36.32) that
disrupted one copy of the COL4A5 gene [20]. Due to the
translocation, the normal X chromosome was preferentially
inactivated, leading to a severe phenotype.
Vetrie et al. [13] were unable to find a correlation
between X-inactivation measured in lymphocytes and
disease severity in a group of 30 heterozygous females
and, based on this result, postulated that lymphocyte X-
inactivation ratios do not accurately reflect X-inactivation
ratios in renal tissue. This possibility is supported by
reports showing that severe skewing of X inactivation
(>90:10) in lymphocytes increases with age, likely due to
selection pressure on peripheral blood cells that rapidly turn
over [18]. Additionally, skewed patterns of X inactivation
are more likely to be found in the blood than in other
tissues, such as buccal and urinary epithelia [18].
Two groups have attempted to use α5(IV) expression in
the EBM as revealed by immunofluorescence microscopy
as a surrogate for X inactivation and α5(IV) expression in
the GBM—with conflicting results. Nakanishi et al. found a
highly significant negative correlation between EBM α5
(IV) expression and urine protein to creatinine ratio in 25
heterozygous females [21]. Masella et al. found no
correlation at all in a study of 22 heterozygous females
using similar methodology [22]. Therefore, it is currently
impossible to accurately predict renal outcomes in females
based on measurements of α5(IV) expression in the skin.
Fig. 2 A natural history study of 195 families with XLAS showed
that nearly 90% of affected males developed end-stage renal disease
(ESRD) by age 40 years. In comparison, 12% of heterozygous females
demonstrated ESRD, which increased to 30–40% after age 60 years.
ESRF End-stage renal failure. Reprinted with permission of the
American Society of Nephrology (Jais et al.: J Am Soc Nephrol
14:2603–2610 [4])
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XLAS
The availability of a transgenic mouse model of XLAS has
allowed us to directly test the influence of skewed X
inactivation ratios on disease outcomes. The XLAS mouse
recapitulates the classic pathological findings of human AS,
including the ultrastructural and α5(IV) immunostaining
findings [23]. Affected male mice develop increasing
proteinuria and azotemia with age and have an average
lifespan of 23 weeks [23]. Heterozygous females have a
less severe but widely variable phenotype, with an average
lifespan of 39 weeks.
In mice, the choice of which X chromosome is
inactivated is influenced by the X controlling element
(Xce) on the X chromosome [24]. Three Xce alleles have
been identified: Xce
a, Xce
b, and Xce
c [24]. Random X
inactivation is observed in mice homozygous for Xce
alleles, whereas mice heterozygous for Xce alleles will
preferentially inactivate Xce
a>Xce
b>Xce
c. Inbred XLAS
mice on a C57BL6/J background possess the Xce
b allele
and would be expected to demonstrate random (50:50) X
inactivation. By crossing heterozygous female XLAS mice
with two strains of 129SvPas mice, we generated two
groups of heterozygous female mice that differed only at
the Xce locus [25]. In group 1 (Xce
a/b), expression of the
mutant Col4a5 allele was favored, while in group 2 (Xce
b/c)
expression of the normal Col4a5 allele was favored. Whole
kidney mRNA expression assays confirmed that the two
groups diverged in X inactivation ratios, with group 1
demonstrating an average ratio of 53:47 (mutant:wild-type)
and group 2 demonstrating a ratio of 46:54 [25]. Despite
this modest skewing of X inactivation ratios overall, there
was a distinct survival advantage in mice in group 2. In
addition, there was a positive correlation between X
inactivation ratio and both urine protein excretion and
plasma urea nitrogen levels at 6 months of age [25]. This
study was the first to confirm a direct effect of X-
inactivation skewing on the XLAS heterozygous female
phenotypes. However, X inactivation ratios only explained
a portion of the observed variability in outcomes. Other
determinants of disease progression in heterozygous
females remain to be discovered.
The applicability of these findings to the prediction of
human XLAS heterozygote outcomes is unclear. Humans
do not have an Xce locus like the mouse; however, other
genes or chromosomal regions are likely to play a similar
role. As discussed above, whole blood lymphocyte X
inactivation ratios may not reflect the state in the kidney.
Unfortunately, it is not possible to perform whole kidney
mRNA assays to evaluate X inactivation ratios in humans.
Consequently, we are currently unable to predict disease
outcomes in heterozygous human females from measure-
ments of X inactivation ratios. Further research into
methods for predicting individual outcomes is needed.
XLAS heterozygotes as kidney donors
Female heterozygotes are often called upon to be kidney
donors for their affected sons or other family members.
Mothers often feel significant guilt for passing the mutant
COL4A5 gene on to their sons, while simultaneously
feeling a moral responsibility to help their sons in any
way they can, particularly by donating their own kidney
[26, 27]. This presents the clinician with the difficult task of
balancing the risk to the donor with the benefits to the
recipient [27]. There is little long-term data regarding
outcomes in either the donors or recipients in this situation.
One report from Germany described five XLAS and one
ARAS heterozygotes who served as kidney donors [26].
One donor had proteinuria prior to transplant and all had
microscopic hematuria. Three donors developed new onset
hypertension and two developed new proteinuria, while
renal function declined by 25–60% over a period of 2–
14 years post-transplant in four of the donors [26]. None of
the donors developed ESRD. For the recipients, there was
100% graft survival at 1 and 5 years, while one kidney
failed after 10 years.
It is recommended that Alport heterozygotes be kidney
donors of last resort [27]. Heterozygous females with
proteinuria or hearing loss should be excluded from
consideration as kidney donors. Heterozygous females with
isolated microscopic hematuria, normal kidney function,
normal blood pressure, and normal hearing can be
considered only after careful counseling about risks.
Research into long-term outcomes and the utility of renal
protective methods for donors, such as angiotensin con-
verting enzyme inhibition, is needed.
Conclusions
There is wide phenotypic variability in disease expression
in heterozygous XLAS females. Heterozygous females with
XLAS are at risk of developing ESRD and sensorineural
hearing loss, although at lower rates than affected males.
Heterozygous XLAS females should not be considered to
be benign carriers, but rather as women at risk for
developing disease. They should be followed clinically in
a similar manner to affected males to evaluate for early
signs of progression. Proteinuria and hearing loss are
predictors of progression to ESRD. When tested directly
in controlled genetic backgrounds, favorable X-inactivation
increases survival and improves clinical parameters in
heterozygousXLASfemalemice.Furtherresearchisrequired
44 Pediatr Nephrol (2012) 27:41–46to determine methods to predict individual outcome for
women with XLAS.
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Review Questions (answers are given following
the references)
1. The percentage of Alport syndrome inherited in an X-
linked manner is:
a. 100%
b. 80%
c. 50%
d. 20%
2. Heterozygous XLAS females can present with:
a. Normal urinalysis
b. Microscopic hematuria
c. Proteinuria
d. Sensorineural hearing loss
e. All of the above
3. The following has been shown to influence disease
outcome in XLAS heterozygous females
a. X inactivation
b. Ethnicity
c. ACE inhibition
d. Pregnancy
e. Genotype
4. Which of the following are risk factors for renal disease
progression in XLAS heterozygous females?
a. Microscopic hematuria
b. Proteinuria
c. Use of hormone replacement therapy
d. Hearing loss
e. B and D
f. B and C
5. X inactivation patterns in this tissue can predict X
inactivation patterns in the kidney
a. Blood lymphocytes
b. Skin
c. Urinary epithelium
d. None of the above
6. Heterozygous XLAS females should be considered as
kidney donors if they meet all of the following criteria
except:
a. Presence of microscopic hematuria
b. Presence of proteinuria
c. Absence of sensorineural hearing loss
d. Absence of hypertension
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